Ablynx N.V. (Euronext:ABLX) and Algeta ASA
(OSE:ALGETA) partnered to evaluate a targeted thorium conjugate (TTC) of
Algeta's thorium-227, an alpha-particle emitting radionuclide, and Ablynx's
Nanobodies against an undisclosed tumor target. Under the one-year research
deal, Ablynx will provide Nanobodies against the target and Algeta will provide
access to chelation and conjugation technologies, as well as thorium-227. Both
companies are also providing resources but are not disclosing details.
It is
definitively the sexiest magic bullet I’ve seen ever! In this attempt just in
ONE vial will be combined the following “hot” things:
1. Targeted approach
2. Thorium-227 radionuclide
3. Nanoparticles
Once again: 3 approaches just in one
vial! Targeting, radiology and nanotechnology! No one investor should resist
putting his own money to such exiting product! I would just recommend spicing
the final medicine with some amount of Viagra… Just for fun… Just to make the medicine sexier!
No comments:
Post a Comment